These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1762639)

  • 1. Forecasting the cost of drug abuse treatment coverage in private health insurance.
    McGuire TG; Shatkin BF
    NIDA Res Monogr; 1991; 113():175-89. PubMed ID: 1762639
    [No Abstract]   [Full Text] [Related]  

  • 2. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic costs of drug abuse: financial, cost of illness, and services.
    Cartwright WS
    J Subst Abuse Treat; 2008 Mar; 34(2):224-33. PubMed ID: 17596904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health insurance coverage questions, public health surveys, and drug abuse.
    Cartwright WS; Woodward AM
    NIDA Res Monogr; 1991; 113():190-204. PubMed ID: 1762640
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of drug abuse treatment: relevant issues and alternative longitudinal modeling approaches.
    Hser YI; Anglin MD
    NIDA Res Monogr; 1991; 113():67-93. PubMed ID: 1762644
    [No Abstract]   [Full Text] [Related]  

  • 6. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managed care, networks and trends in hospital care for mental health and substance abuse treatment in Massachusetts: 1994-1999.
    Fleming E; Lien H; Ma CT; McGuire TG
    J Ment Health Policy Econ; 2003 Mar; 6(1):3-12. PubMed ID: 14578543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insurance mandates and health care costs: requiring insurance companies to cover certain services has defendants and opponents.
    Wasserman S
    State Legis; 2004 Jan; 30(1):19-21. PubMed ID: 14692405
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluating the cost-effectiveness of drug abuse treatment services.
    Apsler R
    NIDA Res Monogr; 1991; 113():57-66. PubMed ID: 1762643
    [No Abstract]   [Full Text] [Related]  

  • 10. Some pitfalls in making cost estimates of state health insurance coverage expansions.
    Long SH; Marquis MS
    Inquiry; 1996; 33(1):85-91. PubMed ID: 8774377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug treatment takes a hit. As substance abuse has surged among teens, coverage for care has been curtailed.
    Gardner J
    Mod Healthc; 1996 Oct; 26(43):66, 68, 70-2. PubMed ID: 10172795
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting the cost of mental health benefits.
    McGuire TG
    Milbank Q; 1994; 72(1):3-23. PubMed ID: 8164609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health care utilization of carpenters with substance abuse-related diagnoses.
    Lipscomb HJ; Dement JM; Li L
    Am J Ind Med; 2003 Feb; 43(2):120-31. PubMed ID: 12541266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A research agenda for economic evaluation of substance abuse services.
    French MT; Drummond M
    J Subst Abuse Treat; 2005 Sep; 29(2):125-37. PubMed ID: 16135341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure to protect: why the individual insurance market is not a viable option for most U.S. families: findings from the Commonwealth Fund Biennial Health Insurance Survey, 2007.
    Doty MM; Collins SR; Nicholson JL; Rustgi SD
    Issue Brief (Commonw Fund); 2009 Jul; 62():1-16. PubMed ID: 19621500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic costs, cost-effectiveness, financing, and community-based drug treatment.
    NIDA Res Monogr; 1991; 113():1-211. PubMed ID: 1762633
    [No Abstract]   [Full Text] [Related]  

  • 17. Women at risk: why many women are forgoing needed health care. An analysis of the Commonwealth Fund 2007 Biennial Health Insurance Survey.
    Rustgi SD; Doty MM; Collins SR
    Issue Brief (Commonw Fund); 2009 May; 52():1-12. PubMed ID: 19434951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral health issue brief: mental health and substance abuse parity: year end report-2002.
    Delaney T; Crean E
    Issue Brief Health Policy Track Serv; 2002 Dec; ():1-16. PubMed ID: 12875267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment for substance use disorders in a privately insured population under managed care: costs and services use.
    Greenfield SF; Azzone V; Huskamp H; Cuffel B; Croghan T; Goldman W; Frank RG
    J Subst Abuse Treat; 2004 Dec; 27(4):265-75. PubMed ID: 15610828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.